OUR WORK_
Metastasis
Dynamics & Micrometastasis
We utilize breast cancer experimental metastasis models to unravel the complexities of the metastatic process, focusing particularly on the early seeding of cancer cells in distant organs and the biology and immunology of micrometastases. These poorly understood areas hold the potential to provide valuable insights for the development of novel therapeutic strategies.
Breast cancer
immunotherapy
Immunotherapy has shown great clinical benefits in different cancer types, but not yet for breast cancer. We seek for the molecular configurations of the different breast cancer subtypes that can render breast cancer more sensitive to immune checkpoint blockade immunotherapy.
RNA THERAPY
Development of a specific mRNA therapy for cell fate differentiation to induce tumor immunogenicity and vulnerability to immunotherapy. RNA therapies represents a unique opportunity to design quick therapies and quick clinical application fullfiling the goal of precision medicine and translational oncology.
TUMOR
PHENOTYPIC HETEROGENEITY
We study specifically these highly aggressive poorly differentiated tumor cells within the tumor heterogeneity of breast cancer. We decipher the dynamics of EMT/MET and cellular plasticity during cancer metastasis. Understanding the phenotypic heterogeneity and cellular plasticity of the tumors, we will be able to find specific therapies to target these slippery cells to conventional therapies used in breast cancer treatment.
OUR RESEARCH
PHILOSOPHY
It goes from the discovery of new fundamental biological knowledge to the generation of translational findings for the quick clinical application of novel therapies to STOP cancer metastasis.
WHY
BREAST CANCER?
It is the most common cancer type among women and the second cause of cancer mortality in females. Our social commitment is to reduce the fear and the pain caused by breast cancer among women by finding new promising therapeutic strategies.
WHY
METASTASIS?
Metastasis accounts for more than 90% of cancer-related deaths. Understanding how to stop dreadful stage will lead to the development of new treatments, which is an imperative clinical need.
Low LCOR allows cancer stem cells hide out
El Instituto Hospital del Mar de Investigaciones Médicas (IMIM) de Barcelona está investigando la utilización de la inmunoterapia -emplear el sistema inmune del paciente para at
New approach radically increases the success of breast cancer immunotherapy
El Instituto Hospital del Mar de Investigaciones Médicas (IMIM) de Barcelona está investigando la utilización de la inmunoterapia -emplear el sistema inmune del paciente para at
Look deep into nature, and then you will understand everything better
― Albert Einstein
PÉREZ-NUÑEZ I, ROZALÉN C, PALOMEQUE JA, SANGRADOR I, DALMAU M, COMERMA L, HERNÁNDEZ-PRAT A, CASADEVALL D, MENENDEZ S, DAN LIU D, SHEN M, BERENGER J, RIUS RUIZ I, PEÑA R, MONTAÑÉS JC, ALBÀ MM, BONNIN S, PONOMARENKO J, R GOMIS R, CEJALVO JM, SERVITJA S, M MARZESE D, MOREY L, VOORWERK L, ARRIBAS J, BERMEJO B, KOK M, PUSZTAI L, KANG Y, ALBANELL J, CELIÀ-TERRASSA T*
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Nature Cancer.
VON LOCQUENGHIEN M, ROZALÉN C, CELIÀ-TERRASSA T
Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. The Journal of Clinical Investigation.
CELIÀ-TERRASSA T*, JOLLY MK
Cancer stem cells and epithelial-to-mesenchymal transition in cancer metastasis. Review in Cold Spring Harbor Perspectives in Medicine.
JOLLY MK, CELIÀ-TERRASSA T*
Dynamics of phenotypic heterogeneity associated with EMT and stemness during cancer progression. Review in Journal of Clinical Medicine.
BREAST CANCER 5-YEAR SURVIVAL RATE
(SEER DATABASE)
